Investors
Corporate Overview
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
Email Alerts
Stock Information
NASDAQ Global Market: AUPH
-0.18
-1.54%
Volume
Upcoming Events
Past Events
Second Quarter 2025 Financial Results Conference Call
Conference Call to Discuss Positive Results from Phase 1 Study of Aritinercept (AUR200)
LUPUS 2025, the 16th International Congress on SLE
2025 Annual General Meeting
First Quarter 2025 Financial Results Conference Call
SEC Filings
Governance
IR Contact
General inquiries can be sent to ir@auriniapharma.com